{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T16:39:10Z","timestamp":1763483950010,"version":"3.45.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ixekizumab is a biologic agent primarily indicated for the treatment of moderate to-severe plaque psoriasis. This study aimed to evaluate the post-marketing safety profile of ixekizumab by analyzing adverse event (AE) reports retrieved from the Food and Drug Administration Adverse Event Reporting System (FAERS) database and VigiAccess databases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four disproportionality analysis methods were employed in this study to detect positive signals associated with ixekizumab, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). Sensitivity analyses were conducted to ensure the robustness of the findings. Additionally, the time to onset of AEs was further analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the FAERS databases and VigiAccess databases, 72,847 AE reports in total. Commonly reported AEs included injection site reactions, hypersensitivity reactions, fungal infections, upper respiratory tract infections, and inflammatory bowel disease. In addition, several unexpected AEs were identified, such as cellulitis, ear infection, bronchitis, herpes zoster, tooth infection, diverticulitis, kidney infection, and gastroenteritis viral. Sensitivity analysis further confirmed the robustness of these findings. Notably, 41.1% of the AEs occurred within the first month after treatment initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study confirmed several known AEs and identified some unexpected AEs, providing preliminary safety insights to guide clinicians in the safe use of ixekizumab in clinical practice. It is important to note that findings from spontaneous adverse event reporting systems are hypothesis-generating and may be limited by underreporting, variable reporting quality, and confounding factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1652401","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:17:42Z","timestamp":1760329062000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases"],"prefix":"10.3389","volume":"12","author":[{"given":"Kaidi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanfeng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinqin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiashu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/13880209.2024.2443415","article-title":"Overview of current research on traditional Chinese medicine in skin disease treatment: a bibliometric analysis from 2014 to 2024","volume":"63","author":"Li","year":"2025","journal-title":"Pharm Biol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3238\/arztebl.m2024.0064","article-title":"Psoriasis as a systemic disease","volume":"121","author":"Mrowietz","year":"2024","journal-title":"Dtsch Arztebl Int"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1093\/rheumatology\/keae198","article-title":"The worldwide prevalence of psoriatic arthritis-a systematic review and meta-analysis","volume":"63","author":"Lembke","year":"2024","journal-title":"Rheumatology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","article-title":"A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience","volume":"42","author":"Kane","year":"2003","journal-title":"Rheumatology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2147\/BTT.S326792","article-title":"Treatment with Ixekizumab following Secukinumab failure in patients with psoriatic arthritis: real-life experience from a resistant population","volume":"15","author":"Berman","year":"2021","journal-title":"Biologics"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40744-023-00553-1","article-title":"A comprehensive review of Ixekizumab efficacy in nail psoriasis from clinical trials for moderate-to-severe psoriasis and psoriatic arthritis","volume":"10","author":"Kirkham","year":"2023","journal-title":"Rheumatol Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s13555-022-00743-9","article-title":"Safety of Ixekizumab in adult patients with moderate-to-severe psoriasis: data from 17 clinical trials with over 18,000 patient-years of exposure","volume":"12","author":"Griffiths","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jaad.2020.11.022","article-title":"Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial","volume":"85","author":"Blauvelt","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/jdv.19682","article-title":"Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5\u202fyears","volume":"38","author":"Mastorino","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1458438","DOI":"10.3389\/fphar.2024.1458438","article-title":"Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1038\/s41598-025-86976-y","article-title":"A real-world pharmacovigilance study of brodalumab based on the FDA adverse event reporting system","volume":"15","author":"He","year":"2025","journal-title":"Sci Rep"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fphar.2020.00315","article-title":"Intravitreal anti-VEGF drugs and signals of dementia and Parkinson-like events: analysis of the VigiBase database of spontaneous reports","volume":"11","author":"Sultana","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40264-013-0075-1","article-title":"Choosing thresholds for statistical signal detection with the proportional reporting ratio","volume":"36","author":"Slattery","year":"2013","journal-title":"Drug Saf"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.numecd.2018.02.014","article-title":"Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems","volume":"28","author":"Raschi","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa189","article-title":"Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials","volume":"59","author":"Genovese","year":"2020","journal-title":"Rheumatology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13075-023-03257-7","article-title":"Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials","volume":"26","author":"Deodhar","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1007\/s12325-022-02126-0","article-title":"Ixekizumab citrate-free formulation: results from two clinical trials","volume":"39","author":"Chabra","year":"2022","journal-title":"Adv Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1517\/14740338.2015.1009036","article-title":"Infection risk associated with anti-TNF-\u03b1 agents: a review","volume":"14","author":"Murdaca","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1517\/14740338.2015.993605","article-title":"Safety issues and concerns of new immunomodulators in rheumatology","volume":"14","author":"Selmi","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.23736\/S2784-8671.20.06580-3","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management","volume":"156","author":"Burshtein","year":"2021","journal-title":"Ital J Dermatol Venerol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13075-020-2099-0","article-title":"Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis","volume":"22","author":"Combe","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1136\/annrheumdis-2021-222027","article-title":"Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure","volume":"81","author":"Deodhar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jamapediatrics.2015.1982","article-title":"Inflammatory bowel disease in children and adolescents","volume":"169","author":"Rosen","year":"2015","journal-title":"JAMA Pediatr"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1124628","DOI":"10.3389\/fphar.2023.1124628","article-title":"IL-17 inhibitor-associated inflammatory bowel disease: a study based on literature and database analysis","volume":"14","author":"Deng","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1159\/000493922","article-title":"Severe de novo ulcerative colitis following ixekizumab therapy","volume":"12","author":"Philipose","year":"2018","journal-title":"Case Rep Gastroenterol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12876-019-1067-0","article-title":"Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report","volume":"19","author":"Smith","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.gastrohep.2020.04.009","article-title":"Debut of inflammatory bowel disease associated to Ixekizumab in patient with moderate, difficult -to-manage psoriasis","volume":"43","author":"Merino","year":"2020","journal-title":"Gastroenterol Hepatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e00316","DOI":"10.14309\/crj.0000000000000316","article-title":"Ixekizumab associated new-onset inflammatory bowel disease","volume":"7","author":"Nazarian","year":"2020","journal-title":"ACG Case Rep J"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjd.14528","article-title":"Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study","volume":"175","author":"Egeberg","year":"2016","journal-title":"Br J Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/ecco-jcc\/jjz152","article-title":"Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease-a systematic review and Meta-analysis","volume":"14","author":"Alinaghi","year":"2020","journal-title":"J Crohns Colitis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"20526","DOI":"10.1038\/s41598-022-24872-5","article-title":"The causal relationship between psoriasis, psoriatic arthritis, and inflammatory bowel diseases","volume":"12","author":"Sun","year":"2022","journal-title":"Sci Rep"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/ecco-jcc\/jjz109","article-title":"Deregulation of long intergenic non-coding RNAs in CD4+ T cells of lamina propria in Crohn's disease through transcriptome profiling","volume":"14","author":"Braga-Neto","year":"2020","journal-title":"J Crohns Colitis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/joim.13282","article-title":"Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach","volume":"290","author":"Hedin","year":"2021","journal-title":"J Intern Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/09546634.2017.1329511","article-title":"Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease","volume":"29","author":"Hohenberger","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/vaccines12030252","article-title":"Herpes zoster and cardiovascular disease: exploring associations and preventive measures through vaccination","volume":"12","author":"Yamaoka-Tojo","year":"2024","journal-title":"Vaccine"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and safety of Ixekizumab in the treatment of radiographic axial Spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheum"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s41927-021-00218-y","article-title":"Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52\u202fweeks","volume":"5","author":"Deodhar","year":"2021","journal-title":"BMC Rheumatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma risk in patients treated with biologic therapy for common inflammatory diseases: a systematic review and Meta-analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.3390\/cancers16122262","article-title":"Malignant melanoma: an overview, new perspectives, and vitamin D signaling","volume":"16","author":"Slominski","year":"2024","journal-title":"Cancer"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jaad.2021.01.084","article-title":"Psoriasis and risk of cutaneous melanoma: a retrospective, comparative, registry-based cohort study","volume":"86","author":"Polesie","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3390\/life11101109","article-title":"Psoriasis therapy and skin Cancer: a review","volume":"11","author":"Butr\u00f3n-Bris","year":"2021","journal-title":"Life (Basel)"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"8114739","DOI":"10.1093\/ced\/llaf169","article-title":"Risk of nonmelanoma skin cancers and cutaneous melanoma after psoralen and ultraviolet a therapy in psoriasis patients: a nationwide Taiwanese cohort study","author":"Ko","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1001\/jamadermatol.2022.3337","article-title":"Association between low-dose methotrexate exposure and melanoma: a systematic review and meta-analysis","volume":"158","author":"Yan","year":"2022","journal-title":"JAMA Dermatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jaad.2022.11.043","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors","volume":"88","author":"Kreher","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/12034754211038509","article-title":"Risk of developing melanoma with systemic agents used to treat psoriasis: a review of the literature","volume":"26","author":"Semaka","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ph17010014","article-title":"Risk of melanoma and non-melanoma skin cancer in patients with psoriasis and psoriatic arthritis treated with targeted therapies: a systematic review and meta-analysis","volume":"17","author":"Krzysztofik","year":"2023","journal-title":"Pharmaceuticals"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.immuni.2009.09.014","article-title":"T helper 17 cells promote cytotoxic T cell activation in tumor immunity","volume":"31","author":"Martin-Orozco","year":"2009","journal-title":"Immunity"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/s43018-023-00610-2","article-title":"Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma","volume":"4","author":"V\u00e1raljai","year":"2023","journal-title":"Nat Can"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1652401\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T16:36:42Z","timestamp":1763483802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1652401\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":54,"alternative-id":["10.3389\/fmed.2025.1652401"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1652401","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"article-number":"1652401"}}